We are live on ! Find out more
LENZ

LENZ Therapeutics
LENZ

60 hedge funds and large institutions have $587M invested in LENZ Therapeutics in 2021 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 20

18% more funds holding

Funds holding: 51 → 60 (+9)

9% more repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 11

0.63% more ownership

Funds ownership: 8.21% → 8.85% (+0.63%)

40% less capital invested

Capital invested by funds: $981M → $587M (-$394M)

75% less funds holding in top 10

Funds holding in top 10: 4 → 1 (-3)

Holders
60
Holders Change
+9
Holders Change %
+17.65%
% of All Funds
1.05%
Holding in Top 10
1
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-75%
% of All Funds
0.02%
New
29
Increased
12
Reduced
11
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$52.6M
2
BlackRock
BlackRock
New York
+$17.9M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$14.1M
4
SFM
Sphera Funds Management
Israel
+$10.7M
5
Federated Hermes
Federated Hermes
Pennsylvania
+$8.6M

Top Sellers

1
SM
SB Management
United Arab Emirates
-$30.5M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$9.22M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$6.2M
4
Goldman Sachs
Goldman Sachs
New York
-$4.24M
5
SCM
Suvretta Capital Management
New York
-$3.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$122M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$101M +$52.6M +355,375 +66%
RCM
3
RA Capital Management
Massachusetts
$44.2M – – –
RSCM
4
Rock Springs Capital Management
Maryland
$34M -$1.59M -10,718 -3%
VA
5
VR Adviser
New York
$26.4M – – –
O
6
OrbiMed
New York
$23.8M +$7.27M +49,085 +31%
Citadel Advisors
7
Citadel Advisors
Florida
$20.5M -$382K -2,579 -1%
LGM
8
Logos Global Management
California
$19.8M +$2.87M +19,364 +13%
Federated Hermes
9
Federated Hermes
Pennsylvania
$17.3M +$8.6M +58,044 +63%
BlackRock
10
BlackRock
New York
$15.6M +$17.9M +120,905 +817%
Janus Henderson Group
11
Janus Henderson Group
United Kingdom
$15.2M -$6.2M -41,847 -23%
DM
12
Deerfield Management
New York
$14.9M – – –
PA
13
Perceptive Advisors
New York
$14.3M – – –
APM
14
Avidity Partners Management
Texas
$12.3M +$286K +1,928 +2%
BOTOTLSJU
15
Board of Trustees of The Leland Stanford Junior University
California
$11.5M -$13.3K -90 -0.1%
AG
16
Artal Group
Luxembourg
$11.5M – – –
Vanguard Group
17
Vanguard Group
Pennsylvania
$11.4M +$14.1M +95,204 +2,221%
Norges Bank
18
Norges Bank
Norway
$9.08M -$3.09M -20,833 -21%
Millennium Management
19
Millennium Management
New York
$8.87M -$1.03M -6,955 -8%
SFM
20
Sphera Funds Management
Israel
$8.71M +$10.7M +72,331 +2,029%
UBS AM
21
UBS AM
Illinois
$7.26M +$1.03M +6,988 +12%
Morgan Stanley
22
Morgan Stanley
New York
$6.78M +$3.18M +21,466 +57%
WP
23
Woodline Partners
California
$4.92M -$205K -1,384 -3%
Jennison Associates
24
Jennison Associates
New York
$4.86M -$76.7K -518 -1%
Geode Capital Management
25
Geode Capital Management
Massachusetts
$4.22M +$5.45M +36,768 New
1
2 3 4

LENZ Hedge Fund Activity: Q3 2021 in Review

60 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q3 2021, worth a combined $587M — down 40% from $981M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new LENZ positions and 20 closed out — a net gain of 9 holders — while 12 added to existing stakes and 11 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $52.6M. The largest seller was SB Management, exiting entirely with an estimated $30.5M sold.

  • 60 institutional investors held LENZ Therapeutics (LENZ) as of Q3 2021, up from 51 in Q2 2021.
  • Funds reported $587M of LENZ Therapeutics stock for Q3 2021, down 40% quarter-over-quarter.
  • 29 funds opened new LENZ Therapeutics positions in Q3 2021 and 20 closed out, a net change of +9 holders.
  • The largest LENZ Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $52.6M added.
  • The largest LENZ Therapeutics seller in Q3 2021 was SB Management, an estimated $30.5M sold.

Based on aggregated 13F filings for Q3 2021.